MODIFICATION
A -- BAA 09-001-Section (H) Subsection (b) Blood substitutes: human derived,
- Notice Date
- 4/20/2011
- Notice Type
- Modification/Amendment
- NAICS
- 541711
— Research and Development in Biotechnology
- Contracting Office
- RDECOM Contracting Center - Natick R&D (RDECOM-CC), ATTN: AMSRD-ACC-N, Natick Contracting Division (R and BaseOPS), Building 1, Kansas Street, Natick, MA 01760-5011
- ZIP Code
- 01760-5011
- Solicitation Number
- W911QY-11-R-SDPP2
- Response Due
- 4/29/2011
- Archive Date
- 6/28/2011
- Point of Contact
- Shawn Haubner, 508-233-6167
- E-Mail Address
-
RDECOM Contracting Center - Natick R&D (RDECOM-CC)
(shawn.haubner@us.army.mil)
- Small Business Set-Aside
- N/A
- Description
- The response date has been changed to 4-29-11. The Naval Health Research center seeks submissions to meet requirements for BAA 09-001, Section (H) Biomedical Translational Initiative, Subsection (b) Blood Substitutes: human derived, temperature stable, lipid reduced plasma products for trauma induced coagulopathy. Please provide a white paper (7-page limit) explaining the capabilities, materials, designs and/or concepts identified above, on company letterhead, either in Microsoft Word or Acrobat Adobe Format in Times New Roman 12-point font or larger. Responses should include patent rights and/or licensure information for any data, product or technology that may be used to accomplish a proposed solution. Please indicate preference as to whether or not any future development rights would be shared with the government if a partnership were to develop. Include additional supporting documentation as applicable. Summary The Committee on Tactical Combat Casualty Care has an urgent need for a dried plasma product for use as transfusion product or resuscitation fluid to replace coagulation factors for non-compressible hemorrhage injuries, or for related indications. It is hypothesized that a dried plasma product could limit preventable fatalities by reducing logistical constraints associated with currently used frozen plasma products and expanding the availability of plasma in military operations. The purpose of this program is to support R&D efforts for the development of a spray dried plasma product for use as transfusion product or resuscitation fluid to replace coagulation factors for non-compressible hemorrhage injuries, or for related indications. Milestones may include IND submission, clinical trials, FDA approval, and various field testing efforts. End User requirements a. Ease of use: plasma product must provide maximum ease of use and be easily accessed, re-suspended and delivered. b. Portability: Product packaging must be light, durable and able to handle harsh conditions. No glass bottles can be used to store product. c. Sustainability: Shelf stable - can be safely stored in a sealed container at a room or ambient temperature for an extended period of time. If you have any questions please contact Shawn Haubner at shawn.haubner@us.army.mil, or call (508) 233-6167.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/notices/0f66035332eb068334e78857be5e8208)
- Record
- SN02429497-W 20110422/110420235651-0f66035332eb068334e78857be5e8208 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |